← All trials
NCT02785705
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2015
- Primary completion
- Aug 1, 2015
- Completion date
- Aug 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 600
- Arms / groups
- 6 / —
- Source
- AACT · pre-existing
Sponsors
- Government of ChinaLead sponsor
- Bureau of Science and Technology of Guangxi Province, ChinaOverall official - principal investigator
- Beijing Tiantan Bio Co., LtdCollaborator
- Government of ChinaReponsible party - principal investigator
- People's Liberation Army of ChinaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.